Friday, August 7th, 2026

Problems in the medicine of Qmed and Lomus Pharmaceuticals

DDA directs to recall LEVOSAFE-500 and ZEFIX-100 from market



KATHMANDU: The Department of Drug Administration (DDA) has found two medicines of two Nepali pharmaceutical companies below the standard and has directed the concerned companies to recall the medicine from the market.

Issuing a statement on Wednesday, DDA has directed Qmed Formulation Pvt Ltd. Chhaling-5, Bhaktapur, Nepal and Lomus Prahmaceuticals Pvt. Ltd. Gothatar, Kathmandu, Nepal to recall the medicines identified as low quality medicines.

The department tested the products of both the pharmaceutical companies and found LEVOSAFE-500 (Levofloxacin 500 mg Tablets IP) of Qmed formulations and ZEFIX-100 (Cefixime 100 mg Dispersible Tablets IP) of Lomus Pharmaceuticals do not comply to IP 2018 with respect to dissolution test.

Both of these drugs are antibiotics.

After getting low quality medicine, the department has taken action as per the Drugs Act 1978.

The department has urged doctors not to prescribe those medicines.

Publish Date : 29 September 2021 14:46 PM

National Planning Commission seeks local data on food systems transformation efforts

KATHMANDU: The National Planning Commission (NPC) has begun coordinating with

Dry landslide damages APF border outpost structures at Tatopani, no casualties

KATHMANDU: A dry landslide damaged multiple structures at the Armed

Three parliamentary committees convening today

KATHMANDU: Three parliamentary committees are holding meetings today. The International

Trump renews effort to curb birthright citizenship through new executive orders

WASHINGTON DC: US President Donald Trump has launched another attempt